Bulletin from the Extraordinary General Meeting of SynAct Pharma AB (publ)

Today, 30 May 2016, an Extraordinary General Meeting of SynAct Pharma AB was held. The following is a summary of the decisions taken. All decisions were taken by the required majority.

Election of a new member of Board of Directors

The General Meeting resolved that the Board of Directors be extended from three to four board members and that Lars Adlersson be elected as a member of the Board of Directors. Other members of the Board of Directors remain in position.

Lars Adlersson, MBA, is a Partner and Senior Adviser at Six Year Plan AB, Chairman of the Board of SwedenBIO and a board member of Lundmark Fondförvaltning. Adlersson has more than 25 years of experience in the life science industry, including as CEO of GlaxoSmithKline in Sweden and Austria, CEO of Medivir (Nasdaq Stockholm: MVIR), Senior Analyst Healthcare at Handelsbanken Capital Markets, Board member of Evolan Pharma and the Läkemedelsindustriföreningen.

Decision on remuneration for the Board of Directors

The General Meeting also decided that Lars Adlersson should receive remuneration of SEK 60 000.

Lund, May 2016
SynAct Pharma AB (publ)

For further information about SynAct Pharma AB, please contact:

Jeppe Øvlesen
CEO, SynAct Pharma AB
Telephone: +45 28 44 75 67
E-mail: [email protected]

Henrik Stage
CFO, SynAct Pharma AB
Telephone: +45 40 26 09 00
E-mail: [email protected]

SynAct Pharma AB, Company registration number 559058-4826, is a biotech company that conducts research and development in inflammatory diseases via the wholly owned Danish subsidiary, SynAct Pharma ApS. The company has a platform technology based on a new class of drug candidate targeting acute deterioration in chronic inflammatory diseases, with the primary purpose of stimulating natural healing mechanisms. SynAct Pharma’s main focus is on the development of the candidate drug AP1189, which strengthens the body’s own cells and fights flares in inflammation by accelerating recovery and thereby reducing the risk of chronic inflammation deterioration.